NRT6008
/ Chengdu New Radiomedicine Technology
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 24, 2025
Safety and Efficacy of NRT6008 in Patients with Unresectable Locally Advanced Pancreatic Cancer (LAPC)
(clinicaltrials.gov)
- P1 | N=58 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2026 ➔ Jun 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027
Enrollment open • Trial completion date • Trial primary completion date • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
August 21, 2024
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)
(clinicaltrials.gov)
- P1 | N=58 | Not yet recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Initiation date: Mar 2024 ➔ Sep 2024
Metastases • Trial initiation date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
February 26, 2024
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)
(clinicaltrials.gov)
- P1 | N=58 | Not yet recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD.
Metastases • New P1 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
1 to 3
Of
3
Go to page
1